Occupational Hand Dermatitis Persists Post-COVID Despite Prevention Efforts

Occupational contact dermatitis is rarely dangerous, but it derails careers and cuts productivity, and among health care workers during the COVID-19 pandemic, it affected an estimated 27.4% within a single year, according to a review published in The Journal of Clinical Medicine.¹

The Most Common Occupational Skin Disease

Occupational contact dermatitis (OCD) accounts for roughly 90% to 95% of occupational dermatoses and falls predominantly on the hands, making it the most common work-related skin disease overall. Though rarely medically dangerous, it imposes a substantial burden through impaired quality of life, lost productivity, and premature exit from affected trades. The World Health Organization's 2025 resolution recognizing skin diseases as a global public health priority has lent new institutional weight to addressing conditions like OCD that were previously treated as a workplace nuisance rather than a public health concern.²

The COVID-19 pandemic intensified that burden considerably, particularly among health care workers whose hand hygiene routines intensified overnight. A new narrative review set out to integrate current evidence on the epidemiology, pathophysiology, diagnosis, prevention, and management of OCD in that post-pandemic context.¹

A Thematic, Non-Systematic Synthesis

The review followed a nonsystematic, thematically organized search strategy rather than a formal PRISMA methodology, integrating evidence across epidemiology, pathophysiology, prevention, and management. Established evidence and the authors' own hypotheses were kept explicitly separate throughout, including a conceptual model proposing that protease-generated LL-37 fragments may modulate staphylococcal quorum sensing, a mechanism the authors labeled a conjecture rather than a demonstrated pathway, with each step marked according to whether supporting evidence was direct, extrapolated, or untested.

Among health care workers, the pooled 1-year prevalence of self-reported hand eczema reached 27.4% (95% CI, 19.3%-36.5%) during the pandemic era. Meta-analytic data cited in the review linked that increased risk principally to frequent handwashing and wet work, rather than to alcohol-based hand rub use, a distinction with direct implications for infection-control policy.

On the treatment side, the review highlighted topical delgocitinib as a recent therapeutic advance for OCD and cautioned that the broader prevention evidence base remains weak. Randomized trials of primary and secondary prevention strategies have been null, in tension with encouraging but uncontrolled results from structured tertiary-prevention programs.

“We argue that the prevention failure is less one of biology than of trial design and measurement,” the authors wrote, outlining the research needed to close that gap going forward.

Delgocitinib Outperformed the Only Approved Systemic Option

Topical delgocitinib, a first-in-class pan-Janus kinase inhibitor now approved for moderate to severe chronic hand eczema in the European Union (2024) and the US (2025), is the first topical agent licensed specifically for the indication, the review noted. In the phase 3 DELTA 1 (NCT04871711) and DELTA 2 (NCT04872101) trials, treatment success at week 16 was achieved by roughly 20% of patients on delgocitinib vs 10% on vehicle in DELTA 1 and 29% vs 7% in DELTA 2. Most notably, the head-to-head DELTA FORCE (NCT05259722) trial compared topical delgocitinib with oral alitretinoin (the only systemic drug licensed for severe chronic hand eczema) in 513 adults with severe disease. Delgocitinib produced a significantly greater reduction in eczema severity scores at week 12 and fewer adverse events (49% vs 76%) over 24 weeks. The review's authors called delgocitinib the field's first major therapeutic advance in decades.

A Narrative Review, by the Authors' Own Framing

The authors explicitly note that their nonsystematic, thematically organized search strategy departs from PRISMA methodology, meaning the review does not apply the same rigor as a formal systematic review in study selection or risk-of-bias assessment.

The trans-kingdom dialogue model proposed around LL-37 fragments and staphylococcal quorum sensing is explicitly presented as an untested conceptual hypothesis rather than an established mechanism and should not be read as clinically actionable until tested.

For occupational health programs and payers covering health care workforces, the review's central message is that handwashing frequency and wet work, not antiseptic choice, should drive prevention policy, and that tertiary-prevention programs, despite lacking randomized confirmation, may currently represent the most promising lever available while better-designed primary-prevention trials are developed. The DELTA FORCE data also give payers a head-to-head comparison to weigh as delgocitinib enters formulary discussions alongside the longer-established oral alitretinoin.

References:

1. Maghiar L, Iftode A, Maghiar TA, et al. Occupational Contact Dermatitis in the Post-COVID Era: From Barrier Dysfunction and Microbiome Dysbiosis to Prevention and Precision Management. J Clin Med. 2026;15(16):6353. doi:10.3390/jcm15166353
2. World Health Organization. Survey: WHA Resolution on Skin Diseases as a Global Public Health Priority. Published 2025. Accessed October 1, 2026. https://www.who.int/news-room/articles-detail/survey-wha-resolution-on-skin-diseases-as-a-global-public-health-priority